Core Insights - Balchem (NASDAQ: BCPC) reported record third-quarter sales, leading to a significant increase in stock price, with shares rising over 5% initially and remaining up by 3.8% later in the day [1][3]. Company Performance - The company specializes in developing, manufacturing, and selling specialty performance ingredients for human and animal nutrition, with a focus on dietary supplements and encapsulation technologies for improved nutrient delivery [3]. - Third-quarter sales grew by 11.5% year over year, driven by market penetration of its unique portfolio and favorable trends in the food and nutrition markets [3]. - Balchem generated $51 million in free cash flow, which was utilized to pay down a significant portion of its debt [4]. Future Prospects - Despite the recent stock surge, Balchem's stock performance has been relatively flat for the year, as investors await results from studies on choline intake and its impact on human health [5]. - The company is investing to double its domestic capacity for nutrient delivery technologies, anticipating strong returns from this investment [5]. - There is an expectation among some investors for further growth in sales and profits in the near future [5].